|
|
|
|
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer
Hortobagyi GN et al.The combination of UFT and leucovorin administered orally in a twice-daily regimen was found to have modest activity. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily...
|
|
|
A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer
UFT, a combination of uracil and ftorafur, was developed to combine the cytotoxic effects of 5-fluorouracil (5-FU) with convenient oral dosing.Leucovorin is combined with UFT to further potentiate the effect of 5-FU on tumor cells. Orally...
|
|
|
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer
_ Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer.
|
|
|
Poniard Pharma's phase 2 trial of Picoplatin in metastatic colorectal cancer meets primary endpoint
Poniard Pharmaceuticals, Inc.(PARD), a biopharmaceutical company focused on innovative oncology therapies, announced final data from a randomized, controlled phase 2 trial of picoplatin in metastatic colorectal cancer (CRC) patients. The study met its...
|
|
|
Picoplatin 'provides alternative' in colorectal cancer treatment
Picoplatin could be used as a neuropathy-sparing alternative to oxaliplatin in the treatment of metastatic colorectal cancer (CRC), it was suggested yesterday (25th January).Biopharmaceutical firm Poniard Pharmaceuticals confirmed that the drug met its...
|
|
|
Poniard Reports Positive Results In Phase 2 Picoplatin Trial
Poniard Pharmaceuticals (Poniard) has reported final data from a randomised, controlled phase 2 trial of Picoplatin in metastatic colorectal cancer (CRC) patients.The study met its primary objective. In the study, Picoplatin, in combination with 5...
|
|
|
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary En
Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets...-- SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall/ -- Search News Releases WordPress Blog URL: Other News Releases in Other News Releases in Journalists and Bloggers...
|
|
|
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary En
- Statistical data support picoplatin as a potential neuropathy-sparing alternative to oxaliplatin - SOUTH SAN FRANCISCO, Calif., Jan.24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company focused on...
|
|
|
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
SOUTH SAN FRANCISCO, Calif., Jan.24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on innovative oncology therapies, today announced final data from a randomized, controlled Phase 2 trial of picoplatin in...
|
